• ShareVault Web Panel: Adoptive Cell Therapy vs. Solid Tumors

    • Share:
    •  
    Name: ShareVault Web Panel: Adoptive Cell Therapy vs. Solid Tumors
    Date: November 21, 2019
    Time: 2:00 PM - 3:30 PM EST
    Website: Learn more!
    Event Description:
    ShareVault Announces Web Panel on Adoptive Cell Therapy vs. Solid Tumors: Who, How, and When?
     
    Just 7 years since Novartis paid UPenn $20M to access Carl June’s anti-CD19 CAR-T technology, the field of adoptive cell therapy (ACT) in cancer has expanded dramatically, both in investment activity and technology proliferation. At present, it is estimated that there are at least 150 pre-commercial ACT-focused companies in the US and EU alone, many of which are less than 5 years old. While some of these newcos are pursuing fast-follower strategies, many are developing novel technology platforms, each with a unique value proposition that has proven sufficient to incentivize investors. 

    While ACTs have yet to score any major wins in solid tumors beyond the early success of TILs, many early-stage clinical programs are slated to readout within the next few years. Join ShareVault on Thursday, November 21 as they ask a panel of experts their views on the most exciting new developments, what they seek to license, what data they must see to do deals, and more. 


     
    Location:
    Web Panel
    Date/Time Information:
    November 21
    2:00 - 3:30 p.m. EST
    Fees/Admission:
    Sign up!  If you can't attend the live session, register anyway, and ShareVault will send you the recording when it becomes available. 
    Set a Reminder:
    Enter your email address below to receive a reminder message.